This site is no longer being updated. Data are accurate as of 2 Dec 2022.

Aivita Biomedical Inc: AV-COVID-19

Aivita Biomedical Inc: AV-COVID-19

Vaccine Type: Replicating Viral Vector

About Trial Phases

Phase 1: 2 Trials

NCT04386252
United States of America
NCT04685603, NCT04690387
Indonesia

Phase 2: 2 Trials

NCT04386252
United States of America
NCT05007496
Indonesia

Phase 3: 0 Trials

There are no trials for this phase.

Approvals

This vaccine is not yet approved.

Registered Trials

NCT05007496
Phase 2
Indonesia
Total Enrollment: 145
Official Trial Registration:
- NCT05007496(Opens in new tab/window)
NCT04386252
Phase 1/2
United States of America
Total Enrollment: 175
Official Trial Registration:
- NCT04386252(Opens in new tab/window)
NCT04685603, NCT04690387
Phase 1
Indonesia
Total Enrollment: 27
Official Trial Registration:
- NCT04685603(Opens in new tab/window)
- NCT04690387(Opens in new tab/window)

© 2023 VIPER Group COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form